These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 18302747)
21. Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). Skriver SK; Laenkholm AV; Rasmussen BB; Handler J; Grundtmann B; Tvedskov TF; Christiansen P; Knoop AS; Jensen MB; Ejlertsen B Acta Oncol; 2018 Jan; 57(1):31-37. PubMed ID: 29168427 [TBL] [Abstract][Full Text] [Related]
22. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798 [TBL] [Abstract][Full Text] [Related]
23. Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. Grassadonia A; Di Nicola M; Grossi S; Noccioli P; Tavoletta S; Politi R; Angelucci D; Marinelli C; Zilli M; Ausili Cefaro G; Tinari N; De Tursi M; Iezzi L; Cioffi P; Iacobelli S; Natoli C; Cianchetti E Ann Surg Oncol; 2014 May; 21(5):1575-82. PubMed ID: 24522992 [TBL] [Abstract][Full Text] [Related]
24. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial. Fontein DB; Charehbili A; Nortier JW; Meershoek-Klein Kranenbarg E; Kroep JR; Putter H; van Riet Y; Nieuwenhuijzen GA; de Valk B; Terwogt JM; Algie GD; Liefers GJ; Linn S; van de Velde CJ Eur J Cancer; 2014 Sep; 50(13):2190-200. PubMed ID: 24970786 [TBL] [Abstract][Full Text] [Related]
26. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Eiermann W; Paepke S; Appfelstaedt J; Llombart-Cussac A; Eremin J; Vinholes J; Mauriac L; Ellis M; Lassus M; Chaudri-Ross HA; Dugan M; Borgs M; Ann Oncol; 2001 Nov; 12(11):1527-32. PubMed ID: 11822750 [TBL] [Abstract][Full Text] [Related]
27. Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. Forero-Torres A; Saleh MN; Galleshaw JA; Jones CF; Shah JJ; Percent IJ; Nabell LM; Carpenter JT; Falkson CI; Krontiras H; Urist MM; Bland KI; De Los Santos JF; Meredith RF; Caterinicchia V; Bernreuter WK; O'Malley JP; Li Y; LoBuglio AF Clin Breast Cancer; 2010 Aug; 10(4):275-80. PubMed ID: 20705559 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea. Beom SH; Oh J; Kim TY; Lee KH; Yang Y; Suh KJ; Moon HG; Han SW; Oh DY; Han W; Kim TY; Noh DY; Im SA Cancer Res Treat; 2017 Apr; 49(2):454-463. PubMed ID: 27554482 [TBL] [Abstract][Full Text] [Related]
31. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. Zdenkowski N; Forbes JF; Boyle FM; Kannourakis G; Gill PG; Bayliss E; Saunders C; Della-Fiorentina S; Kling N; Campbell I; Mann GB; Coates AS; Gebski V; Davies L; Thornton R; Reaby L; Cuzick J; Green M; Ann Oncol; 2016 May; 27(5):806-12. PubMed ID: 26861603 [TBL] [Abstract][Full Text] [Related]
32. Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). Kim J; Lim W; Kim EK; Kim MK; Paik NS; Jeong SS; Yoon JH; Park CH; Ahn SH; Kim LS; Han S; Nam SJ; Kang HS; Kim SI; Yoo YB; Jeong J; Kim TH; Kang T; Kim SW; Jung Y; Lee JE; Kim KS; Yu JH; Chae BJ; Jung SY; Kang E; Choi SY; Moon HG; Noh DY; Han W BMC Cancer; 2014 Mar; 14():170. PubMed ID: 24612502 [TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial. Mohammadianpanah M; Ashouri Y; Hoseini S; Amadloo N; Talei A; Tahmasebi S; Nasrolahi H; Mosalaei A; Omidvari S; Ansari M; Mosleh-Shirazi MA Breast Cancer Res Treat; 2012 Apr; 132(3):853-61. PubMed ID: 22002564 [TBL] [Abstract][Full Text] [Related]
34. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883 [TBL] [Abstract][Full Text] [Related]
35. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. Ueno T; Masuda N; Kamigaki S; Morimoto T; Akiyama F; Kurosumi M; Tsuda H; Mikami Y; Tanaka S; Morita S; Toi M Cancer Med; 2018 Jun; 7(6):2442-2451. PubMed ID: 29733541 [TBL] [Abstract][Full Text] [Related]
36. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Vaklavas C; Roberts BS; Varley KE; Lin NU; Liu MC; Rugo HS; Puhalla S; Nanda R; Storniolo AM; Carey LA; Saleh MN; Li Y; Delossantos JF; Grizzle WE; LoBuglio AF; Myers RM; Forero-Torres A; Breast Cancer Res; 2020 Feb; 22(1):22. PubMed ID: 32070401 [TBL] [Abstract][Full Text] [Related]
37. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of letrozole for advanced breast cancer in postmenopausal patients. Ansari TN; Mahmood A; Hussain I; Samad A J Coll Physicians Surg Pak; 2005 Apr; 15(4):204-6. PubMed ID: 15857590 [TBL] [Abstract][Full Text] [Related]
39. Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Takei H; Suemasu K; Inoue K; Saito T; Okubo K; Koh J; Sato K; Tsuda H; Kurosumi M; Tabei T; Breast Cancer Res Treat; 2008 Jan; 107(1):87-94. PubMed ID: 18043897 [TBL] [Abstract][Full Text] [Related]
40. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]